Potassium channel molecules and uses therefor
    22.
    发明授权
    Potassium channel molecules and uses therefor 失效
    钾通道分子及其用途

    公开(公告)号:US07517659B2

    公开(公告)日:2009-04-14

    申请号:US10701013

    申请日:2003-11-04

    IPC分类号: G01N33/53

    CPC分类号: C07K14/705 A61K38/00

    摘要: The invention provides isolated nucleic acids molecules, designated TWIK nucleic acid molecules, which encode proteins involved in potassium channel mediated activities. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing TWIK nucleic acid molecules, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a TWIK gene has been introduced or disrupted. The invention still further provides isolated TWIK proteins, fusion proteins, antigenic peptides and anti-TWIK antibodies. Diagnostic methods utilizing compositions of the invention are also provided.

    摘要翻译: 本发明提供分离的核酸分子,命名为TWIK核酸分子,其编码参与钾通道介导的活性的蛋白质。 本发明还提供了反义核酸分子,含有TWIK核酸分子的重组表达载体,其中引入了表达载体的宿主细胞,以及引入或破坏TWIK基因的非人类转基因动物。 本发明还进一步提供了分离的TWIK蛋白,融合蛋白,抗原肽和抗TWIK抗体。 还提供了利用本发明组合物的诊断方法。

    Methods and compositions for the treatment and diagnosis of pain disorders using 9805, 2047, 46566, 57749, 577, 20739, 57145, 1465, 1587, 2146, 2207, 32838, 336 or 52908
    24.
    发明申请
    Methods and compositions for the treatment and diagnosis of pain disorders using 9805, 2047, 46566, 57749, 577, 20739, 57145, 1465, 1587, 2146, 2207, 32838, 336 or 52908 审中-公开
    使用9805,2047,46566,57749,577,20739,57145,1465,1587,2166,2207,32838,336或52908来治疗和诊断疼痛障碍的方法和组合物

    公开(公告)号:US20070179102A1

    公开(公告)日:2007-08-02

    申请号:US11232776

    申请日:2005-09-22

    IPC分类号: A61K48/00 C12Q1/68 G01N33/567

    摘要: The present invention relates to methods and compositions for the treatment and diagnosis of pain disorders. The invention further provides methods for identifying a compound capable of treating a pain disorder. In addition, the invention provides a method for treating a subject having a pain disorder, e.g., a pain disorder characterized by aberrant 9805, 2047, 46566, 57749, 577, 20739, 57145, 1465, 1587, 2146, 2207, 32838, 336 and 52908 polypeptide activity or aberrant 9805, 2047, 46566, 57749, 577, 20739, 57145, 1465, 1587, 2146, 2207, 32838, 336 and 52908 nucleic acid expression.

    摘要翻译: 本发明涉及用于治疗和诊断疼痛障碍的方法和组合物。 本发明还提供了鉴定能够治疗疼痛障碍的化合物的方法。 此外,本发明提供了治疗患有疼痛障碍的受试者的方法,例如以异常9805,2047,46566,57749,577,20739,57145,1465,1587,2146,2207,32838,336为特征的疼痛病症 和52908多肽活性或异常9805,2047,46566,57749,577,20739,57145,1465,1587,2166,2207,32838,336和52908核酸表达。

    43239, a novel GPCR-like molecule and uses thereof
    28.
    发明申请
    43239, a novel GPCR-like molecule and uses thereof 审中-公开
    43239,一种新型的GPCR样分子及其用途

    公开(公告)号:US20050089925A1

    公开(公告)日:2005-04-28

    申请号:US10435828

    申请日:2003-05-12

    CPC分类号: C07K14/705 A61K38/00

    摘要: Novel GPCR-like polypeptides, proteins, and nucleic acid molecules are disclosed. In addition to isolated, full-length GPCR-like proteins, the invention further provides isolated GPCR-like fusion proteins, antigenic peptides, and anti-GPCR-like antibodies. The invention also provides GPCR-like nucleic acid molecules, recombinant expression vectors containing a nucleic acid molecule of the invention, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a GPCR-like gene has been introduced or disrupted. Diagnostic, screening, and therapeutic methods utilizing compositions of the invention are also provided.

    摘要翻译: 公开了新的GPCR样多肽,蛋白质和核酸分子。 除了分离的全长GPCR样蛋白之外,本发明还提供了分离的GPCR样融合蛋白,抗原肽和抗GPCR样抗体。 本发明还提供了GPCR样核酸分子,含有本发明的核酸分子的重组表达载体,已经引入了表达载体的宿主细胞和其中已经导入或破坏了GPCR样基因的非人转基因动物 。 还提供了利用本发明组合物的诊断,筛选和治疗方法。